ITF 1129

Drug Profile

ITF 1129

Latest Information Update: 04 Mar 2008

Price : $50

At a glance

  • Originator Italfarmaco
  • Class Anti-ischaemics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Angina pectoris

Most Recent Events

  • 04 Mar 2008 Discontinued - Preclinical for Angina pectoris in Italy (unspecified route)
  • 04 Mar 2008 Discontinued - Preclinical for Angina pectoris in Germany (unspecified route)
  • 10 Oct 1997 A study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top